Nexvet expands veterinary biologics research team
Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team.
CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne.
The centre is designed to bolster Nexvet’s product pipelines and support the company’s existing veterinary drug programs. Nexvet specialises in species-specific biologic treatments for companion animals, produced with its PETization platform.
“I’m delighted to welcome two such experienced research managers to the Nexvet team,” Nexvet chief science officer Dr David Gearing commented. “Their breadth of experience in research and development in biopharmaceuticals will be invaluable.”
He said Nexvet is putting together a team of scientists with diverse biopharma backgrounds for its research activities.
“We are excited about our work on new animal therapies, building on our pioneering research in this field to build a world-class centre for veterinary biologics research,” Gearing said.
In April, Nexvet raised US$31.5 million ($34.9 million) to fund clinical programs for treatment candidates for canine pain, feline pain and canine inflammation.
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
Perioperative trial offers insights into brain cancer treatment
Victorian brain cancer researchers have used an innovative process to learn how a new drug...
New molecular mechanism found for depression
Depression may not only result from simple neuronal damage but can also arise from the...
